版权说明：本文档由用户提供并上传，收益归属内容提供方，若内容存在侵权，请进行举报或认领
文档简介
IressaasFirstLineTherapyinNSCLCIressaasFirstLineTherapyiPersonaldetailsPersonaldetails
Mrs.Chen-LinFemale62y/oNon-smokerPersonaldetailsPersonaldetaiPatienthistoryHistoryCough,leftchestpainfortwomonthsBronchoscopicbiopsyandeffusioncytology:adenocarcinoma.PerformancestatusECOGPS3PrevioustreatmentRefusedanychemotherapyPatienthistoryHistoryInvestigationsImageCTscanofchestrevealedevidenceahugemass,measuredgreaterthan5.0cmindiametertoleftuppelobewithpleuraleffusion.EnlargedLNstoAPwindow.Noevidenceofdistalmets.T4N2M0,stageIIIBInvestigationsImageTreatmentRefusedanychemotherapyagainandagainIressa250mgperdayTreatmentRefusedanychemotherOutcomeTumorsizeisgettingsmalleraftertwoweeksIressatreatment.Followupimagestudy:PRPatientcanwalkwellnow.Iressaisongoingtillnow.Noseveresideeffectexceptskineruptionbutpatientcantolerateit.OutcomeTumorsizeisgettingsIRESSA250mgTwoweekslaterIRESSA250mgTwoweekslaterTenweekslaterIressa250/day,OngoingTenweekslaterIressa250/day,Comments/ConclusionIressaasfirstlinetherapyiseffective.Poorperformancescale:Iressawillimproveitifeffective.FemaleAdenocarcinomaNon-smokerOrientalComments/ConclusionIressaasDiscussionandlearningpointsIressainfirstlinetherapyofNSCLCpatients?Lesssideeffect.Wellqualityoflife.Discussionandlearningpoints[7256]PhaseIItrialoffirst-linegefitinibinpatientsunsuitableforchemotherapywithstageIII/IVnon-small-celllungcancer
D.Swinson.UKGefitinib250mgperdayM/F29/16,unfit/declinedCT25/20Medianage:76PS0/1/2/3:1/15/27/141evaluablePR9.8%SD36.6%PD53.4%Medianoversurvival82daysDiseasecontrolrate46.4%atonemonth[7256]PhaseIItrialoffirstIressaasThirdLineTherapy
(apatientwithboneandbrainmetsafterGemzarpluscisplatinandTaxotere)IressaasThirdLineTherapy
PersonaldetailsPersonaldetails
Mr.ChenMale43Y/OCigarettesmoking:40pack-yearsPersonaldetailsPersonaldetaiPatienthistoryHistoryCough,hemoptysisDxafterimageandbronchoscopicstudiesBronchogeniccarcinoma,LLL,adeno-typePatienthistoryHistoryInvestigationsCTscanTumorsize5.3cmLNsmets,bilateralPleuraleffusion,leftBonescanMultiplebonemetsISSStagingT4N3M1,bonemets,stageIVPerformancestatusECOGPS0InvestigationsCTscanTreatmentGemzar1000mg/M2plusCisplatin75mg/m2PDafterthreecyclestreatmentTaxotere25-30mg/m2,weeklyscheduleSDofChestimagestudiesUnstablegaitwithrefractorynausea,hiccupafter4cyclestaxoteretreatmentMultiplebrainmetsdiagnosedwithCTscanIressa250mgperdayafteracourseofwholebrainirradiation.TreatmentGemzar1000mg/M2plusGemzarpluscisplatinProgressivedisease3cycles11/JUN/2002TaxotereGemzarpluscisplatinProgressi13/NOV/2003Iressa250mgperdayBrainmetsRadiotherapy13/NOV/2003Iressa250mgperd17/DEC/2003rightnowGefinitib17/DEC/2003rightnowGefinitibOutcomeTumorsizeinlungandpericardial,pleuraleffusionvolumereducedafteronemonthGefitinibtreatmentBrainmets,underwellcontrolCNSconditionisstableandhecanwalkanddosomeeasythingECOGPSaround0-1nowIressa250mgperdayisongoingOutcomeTumorsizeinlungandComments/ConclusionIressaiseffectiveeveninlife-threateningconditionoffar-advancedlungcancerBrainmetsisstilleffective?Comments/ConclusionIressaisDiscussionandlearningpointsIressaandbrainbloodbarrier?IressaasthirdlinetherapyisstandardaftertaxaneandcisplatinfailureDiscussionandlearningpointsIrregulartreatmentofIressainapatientofNSCLCIrregulartreatmentofIressaPersonaldetailsPersonaldetails
Mr.ChenMale42y/oCigarettesmoking,20pack-yearsPersonaldetailsPersonaldetaiPatienthistoryHistoryReferredfromotherhospitalbecauseofbronchogeniccarcinoma,RLL,T4N2M1[distalspinalmets]withparaplegia.PerformancestatusECOGPS3-4PrevioustreatmentC/TwithGemzarpluscisplatinPatienthistoryHistoryInvestigationsCTscanofchestTumormass,measured85mmtoRLLwithRLLcollapsePleuraleffusiontorightsideMediastinalLNsmetsBonescanMultipleincreaseduptaketoLumbarandthoracicspineInvestigationsCTscanofchestTreatmentTaxoterewasgivenafteradmissionSteroidandRadiotherapyforspinalmetsPDafterthreecyclesweeklyscheduletherapywithtaxotere25-30mg/M2Iressa250mgQD,onemonthlaterPleuraleffusiondisappearedTumorsizereducedto3.5cmTreatmentTaxoterewasgivenafPDafterGemzarpluscisplatinasfirstlineAndTaxotereassecondlineIressa250mg/daysixmonthslaterPDafterGemzarpluscisplatinOutcomePatientstoppedIressatherapybecauseofeconomicproblemTumorisgettinglarger,measured70mmtwomonthslaterIressa250mgQDagainSDOutcomePatientstoppedIressaStopIressa,sixmonthslaterIressa250mg/dayagain3monthslaterStopIressa,sixmonthslaterIPDagain,3monthslater5monthslaterStopIressaPDagain,3monthslater5montComments/ConclusionIntermittentIressatreatmentdoesstillworkComments/ConclusionIntermittDiscussionandlearningpointsResistancetoIressawillbeamajorproblem?ornot?BecauseofintermittentuseEconomicisstillamajorproblemtomaintaineffectivetreatmentDiscussionandlearningpointsChemotherapyplusGefinitibReasonable?Moreeffective?ChemotherapyplusGefinitibRea[7155]Docetaxelandgefitinibinthefirst-linetreatmentofelderlypatients(>70)withadvancednon-smallcelllungcancer(ANSCLC):ResultsofphaseIItrial
G.Bepler(fromASCO2005)Docetaxel75mg/M2d1assessedevery2cyclesGefitinib250mgstartedd1assessedeverytwomoifaloneuntilPDM/F16/14,medianage74,PS0-121evaluablePR38%SD24%CR0%MS12.4mo1yearsurvival60%FavorabletoxicityRepeated21days[7155]Docetaxelandgefitinib[7259]AphaseI/IItrialofweeklydocetaxelandgefitinibinelderlypatients(≥70)withstageIIIB/IVnon-smallcelllungcancer(NSCLC)
T.E.StinchcombeGefitinib250mgperdayDocetaxeld1,d8,d15PhaseI30mg/M2PhaseII36mg/M2M/F11/9;MedianAge76.2PS0/1/2:3/13/4IIIB/IV:4/16PR29%SD17%PD39%2non-evaluableRepeatedevery28days,untilPDorunacceptabletoxicity[7259]AphaseI/IItrialofwIressaasFirstLineTherapyinNSCLCIressaasFirstLineTherapyiPersonaldetailsPersonaldetails
Mrs.Chen-LinFemale62y/oNon-smokerPersonaldetailsPersonaldetaiPatienthistoryHistoryCough,leftchestpainfortwomonthsBronchoscopicbiopsyandeffusioncytology:adenocarcinoma.PerformancestatusECOGPS3PrevioustreatmentRefusedanychemotherapyPatienthistoryHistoryInvestigationsImageCTscanofchestrevealedevidenceahugemass,measuredgreaterthan5.0cmindiametertoleftuppelobewithpleuraleffusion.EnlargedLNstoAPwindow.Noevidenceofdistalmets.T4N2M0,stageIIIBInvestigationsImageTreatmentRefusedanychemotherapyagainandagainIressa250mgperdayTreatmentRefusedanychemotherOutcomeTumorsizeisgettingsmalleraftertwoweeksIressatreatment.Followupimagestudy:PRPatientcanwalkwellnow.Iressaisongoingtillnow.Noseveresideeffectexceptskineruptionbutpatientcantolerateit.OutcomeTumorsizeisgettingsIRESSA250mgTwoweekslaterIRESSA250mgTwoweekslaterTenweekslaterIressa250/day,OngoingTenweekslaterIressa250/day,Comments/ConclusionIressaasfirstlinetherapyiseffective.Poorperformancescale:Iressawillimproveitifeffective.FemaleAdenocarcinomaNon-smokerOrientalComments/ConclusionIressaasDiscussionandlearningpointsIressainfirstlinetherapyofNSCLCpatients?Lesssideeffect.Wellqualityoflife.Discussionandlearningpoints[7256]PhaseIItrialoffirst-linegefitinibinpatientsunsuitableforchemotherapywithstageIII/IVnon-small-celllungcancer
D.Swinson.UKGefitinib250mgperdayM/F29/16,unfit/declinedCT25/20Medianage:76PS0/1/2/3:1/15/27/141evaluablePR9.8%SD36.6%PD53.4%Medianoversurvival82daysDiseasecontrolrate46.4%atonemonth[7256]PhaseIItrialoffirstIressaasThirdLineTherapy
(apatientwithboneandbrainmetsafterGemzarpluscisplatinandTaxotere)IressaasThirdLineTherapy
PersonaldetailsPersonaldetails
Mr.ChenMale43Y/OCigarettesmoking:40pack-yearsPersonaldetailsPersonaldetaiPatienthistoryHistoryCough,hemoptysisDxafterimageandbronchoscopicstudiesBronchogeniccarcinoma,LLL,adeno-typePatienthistoryHistoryInvestigationsCTscanTumorsize5.3cmLNsmets,bilateralPleuraleffusion,leftBonescanMultiplebonemetsISSStagingT4N3M1,bonemets,stageIVPerformancestatusECOGPS0InvestigationsCTscanTreatmentGemzar1000mg/M2plusCisplatin75mg/m2PDafterthreecyclestreatmentTaxotere25-30mg/m2,weeklyscheduleSDofChestimagestudiesUnstablegaitwithrefractorynausea,hiccupafter4cyclestaxoteretreatmentMultiplebrainmetsdiagnosedwithCTscanIressa250mgperdayafteracourseofwholebrainirradiation.TreatmentGemzar1000mg/M2plusGemzarpluscisplatinProgressivedisease3cycles11/JUN/2002TaxotereGemzarpluscisplatinProgressi13/NOV/2003Iressa250mgperdayBrainmetsRadiotherapy13/NOV/2003Iressa250mgperd17/DEC/2003rightnowGefinitib17/DEC/2003rightnowGefinitibOutcomeTumorsizeinlungandpericardial,pleuraleffusionvolumereducedafteronemonthGefitinibtreatmentBrainmets,underwellcontrolCNSconditionisstableandhecanwalkanddosomeeasythingECOGPSaround0-1nowIressa250mgperdayisongoingOutcomeTumorsizeinlungandComments/ConclusionIressaiseffectiveeveninlife-threateningconditionoffar-advancedlungcancerBrainmetsisstilleffective?Comments/ConclusionIressaisDiscussionandlearningpointsIressaandbrainbloodbarrier?IressaasthirdlinetherapyisstandardaftertaxaneandcisplatinfailureDiscussionandlearningpointsIrregulartreatmentofIressainapatientofNSCLCIrregulartreatmentofIressaPersonaldetailsPersonaldetails
Mr.ChenMale42y/oCigarettesmoking,20pack-yearsPersonaldetailsPersonaldetaiPatienthistoryHistoryReferredfromotherhospitalbecauseofbronchogeniccarcinoma,RLL,T4N2M1[distalspinalmets]withparaplegia.PerformancestatusECOGPS3-4PrevioustreatmentC/TwithGemzarpluscisplatinPatienthistoryHistoryInvestigationsCTscanofchestTumormass,measured85mmtoRLLwithRLLcollapsePleuraleffusiontorightsideMediastinalLNsmetsBonescanMultipleincreaseduptaketoLumbarandthoracicspineInvestigationsCTscanofchestTreatmentTaxoterewasgivenafteradmissionSteroidandRadiotherapyforspinalmetsPDafterthreecyclesweeklyscheduletherapywithtaxotere25-30mg/M2Iressa250mgQD,onemonthlaterPleuraleffusiondisappearedTumorsizereducedto3.5cmTreatmentTaxoterewasgivenafPDafterGemzarpluscisplatinasfirstlineAndTaxotereassecondlineIressa250mg/daysixmonthslaterPDafterGemzarpluscisplatinOutcomePatientstoppedIressatherapybecauseofeconomicproblemTumorisgettinglarger,measured70mmtwomonthslaterIressa250mgQDagainSDOutcomePatientstoppedIressaStopIressa,sixmonthslaterIressa250mg/dayagain3monthslaterStopIressa,sixmonthslaterIPDagain,3monthslater5monthslaterStopIressaPDagain,3monthslater5montC
温馨提示
- 1. 本站所有资源如无特殊说明，都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等，如果需要附件，请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸，网页内容里面会有图纸预览，若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间，仅对用户上传内容的表现方式做保护处理，对用户上传分享的文档内容本身不做任何修改或编辑，并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容，请与我们联系，我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 纺织品质量控制与追溯系统考核试卷
- 电声器件在耳机与耳塞中的应用考核试卷
- 机床功能部件在石油钻采设备中的耐高温性能考核试卷
- 糕点店经营风险与应对策略考核试卷
- 私募股权投资医疗健康行业分析考核试卷
- 静脉治疗护理技术操作标准2023版解读
- 3-2组合逻辑电路的设计
- 小学一年级数学20以内加减法测试题
- 内蒙古医科大学《室内装修工程》2023-2024学年第二学期期末试卷
- 江苏省南通市海安市十校联考2025届初三毕业班联考（二）数学试题试卷含解析
- 国企管理人员招聘考试题库
- 托管老师员工手册
- 中医养生的健康体重
- （2024版）小学二年级孩子如何高效复习语文知识点
- 中石化公司招聘考试真题
- 统编版一年级语文下册部编版第六单元单元教材解读（素材）（课件）
- 乳腺结节手术后的护理
- 2024年口腔医疗相关项目招商引资方案
- 培训固定资产管理制度
- 电厂灰场环境风险评估报告
- 原子核物理实验方法课后习题(附答案)
评论
0/150
提交评论